Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

QR Code

Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer

Aim: To evaluate the efficacy and tolerability of lapatinib (L) and intravenous vinorelbine (V) in patients with metastatic HER2-positive breast cancer who have previously received two lines of anti-HER2 therapy (i.e. trastuzumab [T] with chemotherapy and lapatinib with capecitabine [LC]). Method: C...

Full description

Bibliographic Details
Main Authors:	Chan, Arlene, Shannon, C., De Boer, R., Baron-Hay, S., Redfern, A., Bauwens, A., Craft, P., Webb, S., Townsend, A., Kotasek, D.
Format:	Journal Article
Published:	Wiley-Blackwell Publishing Ltd. 2014
Subjects:	lapatinib/capecitabine HER2-positive breast cancer post-trastuzumab
Online Access:	http://hdl.handle.net/20.500.11937/23969

Similar Items

Capecitabine and vinorelbine in metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2009)

Role of calpain in breast cancer and regulation of therapeutic response to targeted treatment
by: Pu, Xuan
Published: (2016)

Computational pathology and deciphering the complexity of HER2 expression in breast cancer
by: Atallah, Nehal Mohammed
Published: (2025)

Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2013)

Biological significance of human epidermal growth factor receptor 2 (HER2) in breast cancer: effect of oestrogen receptor
by: Ahmad, Dena Akram Jerjees
Published: (2016)

Inhibition of HER2 enriches for Jagged1-dependent breast cancer stem cells: role for membrane Jagged1
by: Shah, Deep, et al.
Published: (2018)

Her2 challenge contest: a detailed assessment of automated her2 scoring algorithms in whole slide images of breast cancer tissues
by: Qaiser, Talha, et al.
Published: (2018)

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
by: Serra, V., et al.
Published: (2011)

HER2 positive metastatic breast cancer: What happens after first line failure?
by: Chan, Arlene
Published: (2016)

A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease
by: Chan, Arlene, et al.
Published: (2012)

Evaluation of the proper dosage of lapatinib and its safety in dogs
by: Tanaka, Yuiko, et al.
Published: (2020)

Phase 1b dose-finding study of motesanib with docetaxel or paclitaxel in patients with metastatic breast cancer
by: De Boer, R., et al.
Published: (2012)

Management of ErbB2-positive breast cancer: Insights from preclinical and clinical studies with lapatinib
by: Vogel, C., et al.
Published: (2010)

TILs in metastatic breast cancer—no surprises, but more questions
by: Chan, Arlene
Published: (2017)

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer
by: Miles, D., et al.
Published: (2013)

The role and regulation of insulin-like peptide 3 (INSL3) in the female reproductive system
by: Dai, Yanzhenzi
Published: (2017)

Open justice and the English criminal process
by: Simpson, Matthew
Published: (2008)

Final Results of the Randomized Phase II NorCap-CA223 Trial Comparing First-Line All-Oral Versus Taxane-Based Chemotherapy for HER2-Negative Metastatic Breast Cancer
by: Cinieri, S., et al.
Published: (2017)

Neratinib in HER-2-positive breast cancer: Results to date and clinical usefulness
by: Chan, Arlene
Published: (2016)

Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer
by: Chan, Arlene, et al.
Published: (2010)

AVEREL: A Randomised Phase 111 Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER-2Positive Locally Recurrent/Metastatic Breast Cancer
by: Gianni, L., et al.
Published: (2013)

RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
by: Baselga, J., et al.
Published: (2017)

BCL-2, HER1, HER2, HER3 and HER4 expression in primary colorectal adenocarcinoma
by: Ahmad Zubir, Nurul Mahirah
Published: (2017)

Neratinib after trastuzumab in patients with HER2-positive breast cancer - Author's reply
by: Chan, Arlene, et al.
Published: (2016)

HerMES: Far infrared properties of known AGN in the HerMES fields
by: Hatziminaoglou, E., et al.
Published: (2010)

Optimising targeted antibodies for the treatment of metastatic solid tumours
by: Herbertson, Rebecca A.
Published: (2009)

Numerical models of solar distillation device: present and previous
by: Ahsan, Amimul, et al.
Published: (2013)

Her beauty & her terror : portrait of an archetypal land
by: Frantom, Michelle
Published: (2014)

An investigation of metastatic colorectal cancer
by: Asiri, Abutaleb
Published: (2018)

Effectiveness of in vitro fertilization in women with previous tubal sterilization
by: Malacova, Eva, et al.
Published: (2015)

Induction of labour with Prostaglandin in previous scar
by: Ismail, Norhashimah, et al.
Published: (2017)

Prevalence and management of HER2/neu-positive early breast cancer in a single institution following availability of adjuvant trastuzumab
by: Chan, Arlene, et al.
Published: (2012)

It's her platform
by: Lim, Teik Huat
Published: (2018)

Metastatic thyroid carcinoma presenting with spinal cord compression.
by: Hassan, H. A., et al.
Published: (2010)

Expression of HER4 isoforms and HER4 localisation in HER2 negative breast cancer cell lines
by: Ali, Nursyazana Aqilah
Published: (2021)

Developing leadership for pre-service teachers: previous concepts and models
by: Amirul Fahmie Abdul Razak,, et al.
Published: (2024)

Her ideal platform
by: Lim, Teik Huat
Published: (2018)

HerMES: The SPIRE confusion limit
by: Nguyen, H., et al.
Published: (2010)

The effect on melanoma risk of genes previously associated with telomere length
by: Iles, M., et al.
Published: (2014)

Adjuvant trastuzumab in HER2-positive breast cancer.
by: Slamon, D., et al.
Published: (2011)